Ami Organics, a R&D driven manufacturer of specialty chemicals with varied end usage, focussed on the development and manufacturing of advanced pharmaceutical intermediates for regulated markets and generic active pharmaceutical ingredients, New Chemical Entities and key starting material for agrochemical and fine chemicals, has reported Q2 FY22 revenue of Rs. 122.3 crore, registering a growth of 34%.

The company has reported Q2 FY22 profit of Rs. 17.5 crore, registering a growth of 15%.   

Commenting on results, Nareshkumar Patel, Executive Chairman & Managing Director, Ami Organics Limited said, “I am happy to report that our maiden results, post successful listing of the shares on the bourses has been better than our expectation with a 51% growth on a YoY basis. The demand environment for our products remains strong in such times of turbulence around the world. We introduced two new products during the H1 FY22, which are import substitutes for China where we are one of the few manufacturers in India with being the only manufacturer having big capacities. We have repaid Rs. 136.3 crore debt which was as per our use of proceeds, and we are now a net debt free company."

EBITDA for the half year came at Rs. 49.5crore, up 43% as compared to Rs. 34.5 crore in H1 FY21. EBITDA for the core business continues to improve but EBITDA for newly acquired facilities was in high single digit where operations were minimal in the first 2 months which have now started to pick up

As per the use of proceeds for the IPO, the company has brought down its debt from Rs. 136.6 crore as of 31st March 2021 to Rs. 10.8 crore.

Ami Organics Limited has developed and commercialised over 450 Pharma Intermediates for APIs across 17 key therapeutic areas since inception and NCE, with a strong focus on R&D across select high-growth high margin chronic therapeutic areas.